决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Erratum: Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.
[本文更正了文章 DOI:10.1016/j.omto.2023.07.003。]
更正:本文更正文章 DOI:10.1016/j.omto.2023.07.003。
[This corrects the article DOI: 10.1016/j.omto.2023.07.003.].
MEMBER ACCOUNT
登录成功会直接打开下一页。